Jump to content

Oxford COVID-19 vaccine prompts immune response among adults old and young, AstraZeneca says


Recommended Posts

Oxford COVID-19 vaccine prompts immune response among adults old and young, AstraZeneca says

By Guy Faulconbridge, Kate Kelland and Kate Holton

 

2020-10-26T061812Z_1_LYNXMPEG9P0DR_RTROPTP_4_HEALTH-CORONAVIRUS-USA-VACCINES.JPG

FILE PHOTO: A test tube labeled with the vaccine is seen in front of AstraZeneca logo in this illustration taken, September 9, 2020. REUTERS/Dado Ruvic/File Photo

 

LONDON (Reuters) - The COVID-19 vaccine being developed by the University of Oxford produces a similar immune response in both older and younger adults, and adverse responses were lower among the elderly, British drug maker AstraZeneca Plc said on Monday.

 

A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people, hammered the global economy and shuttered normal life across the world.

 

"It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher," an AstraZeneca spokesman told Reuters.

 

"The results further build the body of evidence for the safety and immunogenicity of AZD1222," the spokesman said, referring to the technical name of the vaccine.

 

The news that older people get an immune response from the vaccine is positive because the immune system weakens with age and older people are those most at risk of dying from the virus.

 

The Financial Times reported earlier that the vaccine, being developed by Oxford and AstraZeneca, triggers protective antibodies and T-cells in older age groups - among those most at risk from the virus.

 

The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer and BioNTech's candidate.

 

If it works, a vaccine would allow the world to return to some measure of normality after the tumult of the pandemic.

 

Immunogenicity blood tests carried out on a subset of older participants echo data released in July which showed the vaccine generated "robust immune responses" in a group of healthy adults aged between 18 and 55, the Financial Times reported.

 

Details of the finding are expected to be published shortly in a clinical journal, the FT said. It did not name the publication.

 

OXFORD VACCINE

 

British Health Secretary Matt Hancock said a vaccine was not yet ready though he was preparing logistics for a possible roll out.

"I would expect the bulk of the roll out to be in the first half of next year," Hancock told the BBC.

 

Asked if some people could receive a vaccine this year he told the BBC: "I don't rule that out but that is not my central expectation."

 

"We want to be ready in case everything goes perfectly but it's not my central expectation that we'll be doing that this year, but the programme is progressing well, we're not there yet," Hancock said.

 

Called AZD1222 or ChAdOx1 nCoV-19, the vaccine was developed by Oxford University scientists and licensed to AstraZeneca in April, which took on the task of scaling trials and production.

 

The vaccine is likely to provide protection for about a year, CEO Pascal Soriot said in June.

 

The British drugmaker has signed several supply and manufacturing deals with companies and governments around the world as it gets closer to reporting early results of a late-stage clinical trial.

 

AstraZeneca resumed the U.S. trial of the experimental vaccine after approval by U.S. regulators, the company said on Friday.

 

Staff at a London hospital trust have been told to be ready to receive the first batches of the vaccine being developed by the University of Oxford and AstraZeneca Plc, The Sun newspaper reported on Monday.

 

The Sun said the hospital, which was not identified, was told to prepare for the vaccine from the "week commencing the 2 November".

 

reuters_logo.jpg

-- © Copyright Reuters 2020-10-26
 
  • Like 1
Link to post
Share on other sites

No news on the person that died, you know cause of death etc etc.

 

The news sounds promising, albeit I will be holding off as long as possible for any jab.

  • Like 1
  • Sad 1
Link to post
Share on other sites
26 minutes ago, ExpatOilWorker said:

Good news and using chimpanzee cold virus is one of the most complex, but best way of creating immunity. 

And it might help me climb trees better!

  • Haha 2
Link to post
Share on other sites
17 hours ago, madmen said:

Huge win for Thailand who has production rights. Im guessing there will be  a no jab no fly order for farangs at some ridiculous price 🙄

...oh! but they promised no double pricing any longer...not sure when that is/was to commence!

Link to post
Share on other sites
17 hours ago, xylophone said:

And it might help me climb trees better!

..primates are no longer available for trialling...looks like Mice and Men.

  • Haha 1
Link to post
Share on other sites

The only things these trials (may) show -in the best case- is that there is an immune response of some sorts and there are no major side-effects. This does NOT mean that vaccinated individuals are protected from severe COVID-19 infection. With the low prevalence of COVID (typically something like 20-30,000 per million inhabitants in the worst affected countries, this being cumulative data over a long period stretching from Feb to mid October, most of these have healed) a trial with 30,000 people is next to useless to establish efficacy against severe COVID as not enough persons will get infected to make any statistical conclusion vs a placebo (control) group.  There is a good reason that there is now talk of deliberately infecting vaccinated volunteers with COVID to see if they are protected, at least to the extent that they will only get a mild disease.

So don't subscribe to all sorts of conspiracy theories but try to be a bit critical (I have been an ad-hoc reviewer for a high impact Biotechnol. journal for 30 years) of what you read and look at it from various angles. 

  • Like 2
Link to post
Share on other sites
20 hours ago, ukrules said:

 

They've been testing on people far older than the 18 to 55 group - this news isn't very clear but mentions the old news from July that the vaccine works in the 18 to 55 year olds - the new news here is referring to a new study on people over 55 and into old age. Those more at risk.....

 

So there's not a long way to go, it's nearly there....

I noticed it is expected to be valid for one year, an annual event, now there is a money spinner 

  • Like 1
Link to post
Share on other sites
13 minutes ago, rosst said:

I noticed it is expected to be valid for one year, an annual event, now there is a money spinner 

Yep, looks like it'll be an annual jab. But whatever, it's better than what we have now, which is nothing. The optimistic probability is once given to enough people the vaccine will halt the rapid spread, the pandemic will be officially ended, and  covid will become like HIV is today...still there, still very dangerous, but treatable and no longer the huge threat it once was.

Link to post
Share on other sites
14 hours ago, TSF said:

Yep, looks like it'll be an annual jab. But whatever, it's better than what we have now, which is nothing. The optimistic probability is once given to enough people the vaccine will halt the rapid spread, the pandemic will be officially ended, and  covid will become like HIV is today...still there, still very dangerous, but treatable and no longer the huge threat it once was.

I am dissapointed that not enough resources are being dedicated to an effective treatment regime. 

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    No registered users viewing this page.

×
×
  • Create New...